Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 15 · below the Ichimoku cloud · RSI 34 · MACD below its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $100.2K | 0.00% | 237.90K | +34% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a JSPR trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for JSPR.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -19.1 | -6.8 | -36.5 | 6.8 | -11.4 | -49.2 | 49.6 | 12.9 | -18.4 | -14.6 | −72.9% | ||
| 2025 | -71.7 | -2.1 | -27.5 | 27.7 | 0.2 | 0.9 | -47.7 | -3.4 | -15.0 | -4.2 | -19.3 | -0.5 | −91.4% |
| 2024 | 49.3 | 80.4 | 38.2 | -18.7 | 8.8 | -12.6 | -18.5 | 17.9 | -13.7 | 12.6 | 7.7 | -6.3 | +171.0% |
| 2023 | 252.0 | 13.5 | -6.2 | -26.5 | 16.5 | -11.6 | 10.2 | -18.5 | -43.1 | -5.7 | -6.8 | 28.3 | +63.4% |
| 2022 | -39.7 | -20.7 | -5.3 | -14.1 | 3.9 | -39.1 | -2.1 | 0.5 | -58.5 | -7.5 | -14.0 | -23.1 | −93.8% |
| 2021 | 0.6 | 1.4 | -3.1 | 0.5 | -0.4 | 0.3 | -0.3 | 0.6 | 2.9 | -11.0 | -10.2 | -4.3 | −21.6% |
| 2020 | 0.0 | -3.7 | 2.1 | 0.0 | 5.6 | -1.5 | -1.5 | -0.3 | -0.9 | 0.8 | 1.0 | +1.4% |
Buy / hold / sell counts
Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is based in Redwood City, California.